Tim W.
- Country
- Belgium
- Department
- Medical Oncology Department
Research Overview
- A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
- Phase 3 Randomized Double‑Blind Trial of Adjuvant MK‑7684A (Vibostolimab + Pembrolizumab) versus Pembrolizumab in High‑Risk Stage II‑IV Melanoma
Data & Insights
Has run more than one trial at 51 of 65 partner sites.
Specializations
Oncology Focus
This investigator specializes in skin cancer research, with particular emphasis on the treatment and management of melanoma.
- Advanced Melanoma Therapy
- High-risk Resected Melanoma Management
- Skin Cancer Treatment Innovation
Their research interests encompass novel therapeutic approaches in dermatological oncology, focusing on improving patient outcomes in melanoma cases.
Therapeutic Development
The investigator's work centers on evaluating novel therapeutic agents for skin malignancies, particularly in the context of immunotherapy approaches.
- Comparative Treatment Studies
- Immunotherapy Applications
- Treatment Response Assessment
Their research encompasses both adult and pediatric populations affected by skin cancers.
Clinical Outcomes
The investigator focuses on assessing recurrence-free survival in patients with skin cancer, particularly in high-risk populations.
- Treatment Efficacy Assessment
- Patient Survival Analysis
- Risk Factor Evaluation
Their work contributes to understanding long-term outcomes in melanoma treatment strategies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.